Fabio Stagno

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6198527/publications.pdf

Version: 2024-02-01

212	4,048	117571	149623
papers	citations	34 h-index	56 g-index

213	213	213	4175
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	COVIDâ€19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. British Journal of Haematology, 2022, 196, 559-565.	1.2	20
2	Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study). Frontiers in Oncology, 2022, 12, 835563.	1.3	6
3	Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection. Cancers, 2022, 14, 1173.	1.7	4
4	Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. Diagnostics, 2022, 12, 1051.	1.3	3
5	Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia. Leukemia and Lymphoma, 2021, 62, 669-678.	0.6	10
6	Nextâ€generation sequencing improves BCRâ€ABL1 mutation detection in Philadelphia chromosomeâ€positive acute lymphoblastic leukaemia. British Journal of Haematology, 2021, 193, 271-279.	1.2	4
7	Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study. Cancer Medicine, 2021, 10, 1726-1737.	1.3	9
8	Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Venetoclax-Loaded Immunoliposome. Cancers, 2021, 13, 1311.	1.7	21
9	Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study. Leukemia, 2021, 35, 1814-1816.	3.3	3
10	Myeloma Patient With Brugada Syndrome and Successful Lenalidomide Treatment. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e456-e459.	0.2	0
11	Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib. Frontiers in Oncology, 2021, 11, 672287.	1.3	10
12	Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network. Frontiers in Oncology, 2021, 11, 739171.	1.3	6
13	A Novel System for Semiautomatic Sample Processing in Chronic Myeloid Leukaemia: Increasing Throughput without Impacting on Molecular Monitoring at Time of SARS-CoV-2 Pandemic. Diagnostics, 2021, 11, 1502.	1.3	1
14	Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study. Acta OncolÃ³gica, 2021, 60, 1527-1533.	0.8	2
15	Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib. Annals of Hematology, 2021, 100, 2005-2014.	0.8	14
16	A Treatment-free Interval Allowed by Ponatinib as Fourth-line Therapy. Cancer Diagnosis & Prognosis, 2021, 1, 19-22.	0.3	2
17	Combined Inhibition of Bcl2 and Bcr-Abl1 Exercises Anti-Leukemia Activity but Does Not Eradicate the Primitive Leukemic Cells. Journal of Clinical Medicine, 2021, 10, 5606.	1.0	6
18	Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors. International Journal of Cardiology, 2020, 301, 163-166.	0.8	21

#	Article	IF	Citations
19	Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. Leukemia, 2020, 34, 488-498.	3.3	35
20	Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia. HemaSphere, 2020, 4, e497.	1.2	14
21	Second-line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-intolerant Chronic Myeloid Leukemia Patients. Anticancer Research, 2020, 40, 5313-5317.	0.5	4
22	On the road to treatment-free remission in chronic myeloid leukemia: what about â€˜the othersâ€™?. Expert Review of Anticancer Therapy, 2020, 20, 1075-1081.	1.1	4
23	Optimal Response in a Patient With CML Expressing BCRâ€“ABL1 E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report. In Vivo, 2020, 34, 1481-1486.	0.6	3
24	Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions. Blood Cancer Discovery, 2020, 1, 48-67.	2.6	30
25	Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors. Annals of Hematology, 2020, 99, 1525-1530.	0.8	9
26	Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study. Blood Cancer Journal, 2020, 10, 66.	2.8	6
27	Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia. Frontiers in Oncology, 2020, 10, 883.	1.3	18
28	Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey. Leukemia, 2020, 34, 2260-2261.	3.3	57
29	Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation. Blood, 2020, 136, 2237-2240.	0.6	13
30	Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. Blood, 2020, 135, 534-541.	0.6	61
31	Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions. Blood Cancer Discovery, 2020, 1, 48-67.	2.6	1
32	Do Not Miss Karyotyping at Chronic Myeloid Leukemia Diagnosis: An Italian Campus CML Study on the Role of Complex Variant Translocations. Blood, 2020, 136, 43-44.	0.6	2
33	Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study. Blood, 2020, 136, 47-48.	0.6	0
34	Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study. Blood, 2020, 136, 45-46.	0.6	1
35	Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib. Blood, 2020, 136, 8-9.	0.6	0
36	Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline. Annals of Hematology, 2019, 98, 2329-2338.	0.8	17

#	Article	IF	Citations
37	Rapid decline of Philadelphiaâ€‘positive metaphases after nilotinib treatment in a cml patient expressing a rare e14a3 bcrâ€‘abl1 fusion transcript: A case report. Oncology Letters, 2019, 18, 2648-2653.	0.8	6
38	BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors. Frontiers in Oncology, 2019, 9, 764.	1.3	12
39	TREATMENT PATTERNS IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKAEMIA IN ROUTINE CLINICAL PRACTICE: THE SIMPLICITY ITALIAN POPULATION. Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019025.	0.5	7
40	Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report. Anticancer Research, 2019, 39, 3949-3954.	0.5	10
41	Efficacy of Nilotinib in a CML Patient Expressing the Three-way Complex Variant Translocation t(2;9;22). Anticancer Research, 2019, 39, 3893-3899.	0.5	13
42	Management of Chronic Myeloid Leukemia in Advanced Phase. Frontiers in Oncology, 2019, 9, 1132.	1.3	54
43	Successful Management of a Pregnant Patient With Chronic Myeloid Leukemia Receiving Standard Dose Imatinib. In Vivo, 2019, 33, 1593-1598.	0.6	8
44	Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib. International Journal of Molecular Sciences, 2019, 20, 2226.	1.8	16
45	Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention. International Journal of Cardiology, 2019, 288, 124-127.	0.8	19
46	Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the realâ€‘life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. Hematological Oncology, 2019, 37, 296-302.	0.8	53
47	Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. Haematologica, 2019, 104, 1589-1596.	1.7	58
48	Colony-Forming Cell Assay Detecting the Co-Expression of <i>JAK2</i>^{V617F} and <i>BCR-ABL1</i> in the Same Clone: A Case Report. Acta Haematologica, 2019, 141, 261-267.	0.7	10
49	Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. Cancer Medicine, 2019, 8, 2041-2055.	1.3	63
50	Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53. Frontiers in Oncology, 2019, 9, 57.	1.3	22
51	Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. Blood Advances, 2019, 3, 4280-4290.	2.5	66
52	Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper. Journal of Hematology and Oncology, 2019, 12, 131.	6.9	45
53	The Q-LAMP Method Represents a Valid and Rapid Alternative for the Detection of the BCR-ABL1 Rearrangement in Philadelphia-Positive Leukemias. International Journal of Molecular Sciences, 2019, 20, 6106.	1.8	7
54	B-ALL Relapses After Autologous Stem Cell Transplantation Associated With a Shift from e1a2 to e14a2 BCR-ABL Transcripts: A Case Report. Anticancer Research, 2019, 39, 431-435.	0.5	13

#	Article	IF	Citations
55	Increased Tumour Burden over a 36 Month Period in Chronic Myeloid Leukemia Patients Following Imatinib Discontinuation: Role of Digital PCR. Blood, 2019, 134, 29-29.	0.6	2
56	Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial. Blood, 2019, 134, 4145-4145.	0.6	3
57	Detection of Actionable BCR-ABL1 Kinase Domain (KD) Mutations in Chronic Myeloid Leukemia (CML) Patients with Failure and Warning Response to Tyrosine Kinase Inhibitors (TKIs): Potential Impact of Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR) on Clinical Decision Making. Blood, 2019, 134, 661-661.	0.6	5
58	Dose Optimization in Elderly CML Patients Treated with Bosutinib after Intolerance or Failure of First-Line Tyrosine Kinase Inhibitors. Blood, 2019, 134, 496-496.	0.6	13
59	A 14q32.31 Genomic-Imprinted DLK1-DIO3 microrna promotes Leukemogenesis By Inducing Stem Cell Quiescence and Inhibiting NK Cell Anti-Cancer Immunity. Blood, 2019, 134, 4141-4141.	0.6	1
60	Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients. Blood, 2019, 134, 1714-1714.	0.6	0
61	Monocytic myeloidâ€derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib. Journal of Cellular and Molecular Medicine, 2018, 22, 1070-1080.	1.6	36
62	Healthâ€related quality of life in patients with chronic myeloid leukemia receiving firstâ€line therapy with nilotinib. Cancer, 2018, 124, 2228-2237.	2.0	22
63	Cardiovascular toxicity in patients with chronic myeloid leukemia treated with secondâ€generation tyrosine kinase inhibitors in the realâ€life practice: Identification of risk factors and the role of prophylaxis. American Journal of Hematology, 2018, 93, E159-E161.	2.0	26
64	Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. Annals of Hematology, 2018, 97, 95-100.	0.8	32
65	Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia. Molecular Cancer, 2018, 17, 56.	7.9	53
66	SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub. Nature Communications, 2018, 9, 2192.	5.8	66
67	Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Ponatinib in the Real-Life Practice: Prophylaxis and Identification of Risk Factors. Blood, 2018, 132, 3006-3006.	0.6	1
68	Comparative Monitoring of Minimal Residual Disease (MRD) By RT-Quantitative (RT-qPCR) and Digital PCR (dPCR) in Ph+ Chronic Myeloid Leukemia (CML) Patients Treated with TKIs for Recognition of Stable Deep Molecular Response (DMR) and Identification of Best Candidates to TKIs Treatment Discontinuation. Blood, 2018, 132, 3012-3012.	0.6	1
69	Imatinib Suspension and Validation (ISAV) Study: Final Results at 79 Months. Blood, 2018, 132, 461-461.	0.6	8
70	Chronic Myeloid Leukemia Italian Multicenter Observational Study (CML-IT-MOS): Clinical Characteristics of Chronic Myeloid Leukemia (CML) Patients Treated in Real-Life between 2012 and 2016 in 66 Italian Hematology Centers of the Gimema Study Group. Blood, 2018, 132, 45-45.	0.6	4
71	One Size Does Not Fit to All: Intolerant or Resistant CML Patients Could Benefit from Different Ponatinib Starting Dose Strategies. Multicenter Italian Experience. Blood, 2018, 132, 1732-1732.	0.6	1
72	Compound BCR-ABL1 Kinase Domain Mutants: Prevalence, Spectrum and Correlation with Tyrosine Kinase Inhibitor Resistance in a Prospective Series of Philadelphia Chromosome-Positive Leukemia Patients Analyzed By Next Generation Sequencing. Blood, 2018, 132, 789-789.	0.6	3

#	Article	IF	Citations
73	The Use of EUTOS Long-Term Survival Score Instead of Sokal Score Is Strongly Advised in Elderly Chronic Myeloid Leukemia Patients. Blood, 2018, 132, 44-44.	0.6	8
74	Outcome of 472 Chronic Myeloid Leukemia Patients Treated with Frontline Nilotinib: A Gimema CML WP Analysis. Blood, 2018, 132, 458-458.	0.6	3
75	Abstract 1134: The tumor suppressor activity of miR-300 is detrimental for leukemia development but required for leukemia stem cell maintenance. , 2018, , .		0
76	Frontline Treatment with Dasatinib in Very Elderly Patients (> 75 Years) with Chronic Myeloid Leukemia: Is It Feasible?. Blood, 2018, 132, 5438-5438.	0.6	0
77	Real Life Evaluation of Efficacy and Safety of Bosutinib Therapy in Chronic Myeloid Leukemia Patients. Blood, 2018, 132, 3021-3021.	0.6	0
78	First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable Molecular Response. Blood, 2018, 132, 4251-4251.	0.6	0
79	Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia. Haematologica, 2017, 102, 1530-1536.	1.7	15
80	Impact of Arterial Thrombotic Events on the Outcome of Chronic Myeloid Leukemia Patients Treated with Nilotinib First-Line: A GIMEMA CML WP Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S313-S314.	0.2	1
81	High BCRâ€“ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib. Clinical Cancer Research, 2017, 23, 7189-7198.	3.2	34
82	Establishing a National Network of Laboratories Using Next Generation Amplicon Deep Sequencing for BCR-ABL1 Kinase Domain Mutation Screening in Philadelphia Chromosome-Positive Leukemias: the â€˜ NEXT-IN-CML' Study. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S310-S311.	0.2	0
83	A populationâ€based study of chronic myeloid leukemia patients treated with imatinib in first line. American Journal of Hematology, 2017, 92, 82-87.	2.0	27
84	Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients. PLoS ONE, 2016, 11, e0158392.	1.1	30
85	Rotation of nilotinib and imatinib for firstâ€line treatment of chronic phase chronic myeloid leukemia. American Journal of Hematology, 2016, 91, 617-622.	2.0	10
86	Frontline Dasatinib Treatment in a â€œReal-Lifeâ€•Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia. Neoplasia, 2016, 18, 536-540.	2.3	24
87	Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. Haematologica, 2016, 101, 1200-1207.	1.7	22
88	The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia. Annals of Hematology, 2016, 95, 211-219.	0.8	18
89	Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes. Expert Review of Anticancer Therapy, 2016, 16, 273-278.	1.1	54
90	Dasatinib first-line: Multicentric Italian experience outside clinical trials. Leukemia Research, 2016, 40, 24-29.	0.4	6

#	Article	IF	Citations
91	Impact of Age on Efficacy, Safety, and Long-Term Outcome of Chronic Myeloid Leukemia (CML) Patients Treated in First-Line with Nilotinib: An Analysis of the Gimema CML Working Party. Blood, 2016, 128, 3068-3068.	0.6	1
92	Prognostic Value of BCR-ABL1 Transcript Type in Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib. Blood, 2016, 128, 3070-3070.	0.6	10
93	Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. Oncotarget, 2016, 7, 80083-80090.	0.8	24
94	A Population-Based Study of Chronic Myeloid Leukemia Treated with Imatinib in First Line. Blood, 2016, 128, 3076-3076.	0.6	0
95	Age and d<scp>PCR</scp> can predict relapse in <scp>CML</scp> patients who discontinued imatinib: The <scp>ISAV</scp> study. American Journal of Hematology, 2015, 90, 910-914.	2.0	181
96	Differences among young adults, adults and elderly chronic myeloid leukemia patients. Annals of Oncology, 2015, 26, 185-192.	0.6	72
97	Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia. Haematologica, 2015, 100, 1146-1150.	1.7	39
98	Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment. Blood Cancer Journal, 2015, 5, e347-e347.	2.8	29
99	Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia, 2015, 29, 1823-1831.	3.3	77
100	Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. Leukemia Research, 2015, 39, 1055-1059.	0.4	57
101	Monocytic Myeloid Derived Suppressor CELLS (M-MDSC) As Prognostic Factor in Chronic Myeloid Leukemia Patients Treated with Dasatinib. Blood, 2015, 126, 2767-2767.	0.6	3
102	Imatinib Suspension and Validation (ISAV) Study: Results at 24 Months. Blood, 2015, 126, 2775-2775.	0.6	3
103	Long-Term Outcome to First-Line Imatinib according to 2013 European LeukemiaNet Response Criteria: a GIMEMA CML WP Analysis. Blood, 2015, 126, 2792-2792.	0.6	2
104	High BCR-ABL/GUSIS Levels at Diagnosis Are Associated with Unfavorable Responses to Standard Dose Imatinib. Blood, 2015, 126, 4049-4049.	0.6	1
105	Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myeloid Leukemia: Comparison with FISH and PCR Techniques. PLoS ONE, 2015, 10, e0130360.	1.1	4
106	Mesenchymal STEM CELLS Favor Tumor Growth By Generating Granulocyte-like Myeloid Derived Suppressor CELLS in CML Patients. Blood, 2015, 126, 4018-4018.	0.6	0
107	Prospective Metabolic and Cardiovascular Assessment in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib 300 Mg Bid Frontline in the Gimema 0811 Trial. Blood, 2015, 126, 4046-4046.	0.6	0
108	Myeloid Derived Suppressor Cells (MDSCs) Are Increased and Exert Immunosuppressive Activity Together with Polymorphonuclear Leukocytes (PMNs) in Chronic Myeloid Leukemia Patients. PLoS ONE, 2014, 9, e101848.	1.1	71

#	Article	IF	Citations
109	Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era. American Journal of Hematology, 2014, 89, 119-124.	2.0	14
110	IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation. Carcinogenesis, 2014, 35, 1132-1143.	1.3	33
111	Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival. Leukemia Research, 2014, 38, 1173-1176.	0.4	30
112	Russo D, Martinelli G, Malagola M, et al. Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. Blood. 2013;121(26):5138-5144.. Blood, 2014, 123, 2902-2902.	0.6	0
113	Gimema Registry of Conception/Pregnancy in Adult Patients Diagnosed with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs). Blood, 2014, 124, 1806-1806.	0.6	5
114	The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis. Blood, 2014, 124, 813-813.	0.6	4
115	Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. Hematological Oncology, 2013, 31, 103-109.	0.8	59
116	SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation. BMC Cancer, 2013, 13, 60.	1.1	15
117	Imatinib in Very Elderly Patients with Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Study. Drugs and Aging, 2013, 30, 629-637.	1.3	36
118	Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia. Annals of Hematology, 2013, 92, 179-183.	0.8	12
119	Suppression of Survivin Induced by a BCR-ABL/JAK2/STAT3 Pathway Sensitizes Imatinib-Resistant CML Cells to Different Cytotoxic Drugs. Molecular Cancer Therapeutics, 2013, 12, 1085-1098.	1.9	59
120	Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia, 2013, 27, 1511-1519.	3.3	119
121	Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. Blood, 2013, 121, 5138-5144.	0.6	49
122	Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. Haematologica, 2013, 98, 399-403.	1.7	42
123	Nuclear Translocation of Heme Oxygenase-1 Confers Resistance to Imatinib in Chronic Myeloid Leukemia Cells. Current Pharmaceutical Design, 2013, 19, 2765-2770.	0.9	80
124	High BCR-ABL/GUSIS Levels At Diagnosis Are Associated With Unfavorable Responses To Imatinib. Blood, 2013, 122, 1495-1495.	0.6	4
125	Frontline Treatment With Imatinib Mesylate in Chronic Myeloid Leukemia Patients in Early Chronic Phase: a Very Long-Term Analysis by the GIMEMA CML Working Party. Blood, 2013, 122, 258-258.	0.6	2
126	Validation of Digital-PCR Analysis through Programmed imatinib Interruption in Q-RT-PCR Negative Chronic Myeloid Leukemia Patients. Blood, 2013, 122, 4040-4040.	0.6	0

#	Article	IF	Citations
127	Myeloid Derived Suppressor Cells (MDSCs) Are Increased and Exert Immunosuppressive Activity In CML Patients At Diagnosis. Blood, 2013, 122, 2711-2711.	0.6	0
128	Hyperdiploidy Associated with a High BCR-ABL Transcript Level May Identify Patients at Risk of Progression in Chronic Myeloid Leukemia. Acta Haematologica, 2012, 127, 7-9.	0.7	16
129	Diagnosis of Blastic Phase of Chronic Myeloid Leukemia. Acta Haematologica, 2012, 127, 198-198.	0.7	0
130	Infliximab therapy in hematologic malignancies: handle with care (Comment). Haematologica, 2012, 97, e26-e26.	1.7	2
131	Increased phosphoâ€m<scp>TOR</scp> expression in megakaryocytic cells derived from <scp>CD</scp>34+ progenitors of essential thrombocythaemia and myelofibrosis patients. British Journal of Haematology, 2012, 159, 237-240.	1.2	15
132	Personalized strategies for CML patients considering discontinuation of tyrosine kinase inhibitors treatment. Leukemia Research, 2012, 36, 1208-1209.	0.4	3
133	Effects of secondâ€generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors. Hematological Oncology, 2012, 30, 27-33.	0.8	26
134	Clinical relevance of the association of interferon alfa to imatinib in chronic myeloid leukemia therapy. International Journal of Hematology, 2012, 96, 142-143.	0.7	1
135	Towards a need to a â€œbiological Sokal riskâ€•in the era of tyrosine kinase inhibitors in choosing front-line therapy in chronic myeloid leukemia. Leukemia Research, 2012, 36, 803.	0.4	3
136	The BCR-ABL Transcript Levels At 3 and 6 Months Predict the Long-Term Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Imatinib Mesylate: A Gimema CML WP Analysis. Blood, 2012, 120, 1678-1678.	0.6	14
137	The BCR-ABL1 Transcript Type Does Not Influence the Response and the Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib. Blood, 2012, 120, 1680-1680.	0.6	5
138	High BCR-ABL Levels At Diagnosis Are Associated with Unfavorable Responses to Imatinib Mesylate.. Blood, 2012, 120, 2790-2790.	0.6	3
139	Five-Year Results of Nilotinib 400 Mg BID in Early Chronic Phase Chronic Myeloid Leukemia (CML): High Rate of Deep Molecular Response - Update of the Gimema CML WP Trial CML0307. Blood, 2012, 120, 3784-3784.	0.6	5
140	Myeloid-Derived Suppressor Cells Increase in Chronic Myeloid Leukemia and Exert Immune Suppressive Activity.. Blood, 2012, 120, 2779-2779.	0.6	0
141	Fatigue Is the Major Aspect Compromising Health-Related Quality of Life of Chronic Myeloid Leukemia Patients Receiving Long-Term Imatinib Therapy. Blood, 2012, 120, 4234-4234.	0.6	0
142	Cytogenetic and Molecular Responses At 3 Months Are Associated with A Better Outcome in Early Chronic Phase (ECP) Chronic Myeloid Leukemia (CML) Patients Treated with Nilotinib.. Blood, 2012, 120, 2797-2797.	0.6	2
143	Imatinib discontinuation: realistic for patients with chronic myeloid leukaemia achieving complete molecular remission?. Lancet Oncology, The, 2011, 12, 118.	5.1	3
144	Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. Haematologica, 2011, 96, 1457-1461.	1.7	58

#	Article	IF	Citations
145	Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells. European Journal of Haematology, 2011, 86, 216-225.	1.1	6
146	Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. Leukemia Research, 2011, 35, 1164-1169.	0.4	28
147	Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with secondâ€generation tyrosine kinase inhibitors. American Journal of Hematology, 2011, 86, 523-525.	2.0	7
148	Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib. Journal of the National Cancer Institute, 2011, 103, 553-561.	3.0	362
149	BRIT1/MCPH1 Expression in Chronic Myeloid Leukemia and Its Regulation of the G2/M Checkpoint. Acta Haematologica, 2011, 126, 205-210.	0.7	34
150	Early CP CML, Nilotinib 400 mg Twice Daily Frontline: Beyond 3 Years, Results Remain Excellent and Stable (A GIMEMA CML Working Party Trial). Blood, 2011, 118, 2756-2756.	0.6	7
151	Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (<400 mg daily) Enough?. Blood, 2011, 118, 2770-2770.	0.6	1
152	Alternating Nilotinib 400 mg twice daily and Imatinib 400 mg once daily as Frontline Treatment of Ph+ Chronic Myeloid Leukemia. A Phase 2 Multicentric Study of the GIMEMA CML Working Party. Blood, 2011, 118, 453-453.	0.6	1
153	Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years,. Blood, 2011, 118, 3766-3766.	0.6	0
154	Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year. Blood, 2011, 118, 1682-1682.	0.6	0
155	Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509. Blood, 2011, 118, 786-786.	0.6	5
156	APPLICATION of EUTOS SCORE IN CHRONIC Myeloid LEUKEMIA AFFECTING VERY Elderly (>75 years) PATIENTS. Blood, 2011, 118, 1686-1686.	0.6	0
157	Age Influences Initial Dose and Compliance to Imatinib In Chronic Myeloid Leukemia Elederly Patients but Concomitant Comorbidities Appear to Influence Overall and Event-Free Survival. Blood, 2011, 118, 2751-2751.	0.6	1
158	The importance of comorbidity and the usefulness of therapeutic early shift in the management of CML patients. Clinical Management Issues, 2011, 5, 3-4.	0.3	0
159	Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3â€year followâ€up. American Journal of Hematology, 2010, 85, 375-377.	2.0	10
160	Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients. American Journal of Hematology, 2010, 85, 960-963.	2.0	13
161	Concomitant use of imatinib and warfarin in chronic phase chronic myeloid leukemia patients does not interfere with drug efficacy. Leukemia Research, 2010, 34, e224-e225.	0.4	4
162	Utility of Flow Cytometry as a Screening Tool for Transplant Donors for Chronic Lymphocytic Leukemia. Acta Haematologica, 2010, 123, 235-236.	0.7	0

#	Article	IF	Citations
163	Unsuccessful Dasatinib Therapy in a Refractory Patient with Chronic Lymphocytic Leukemia. Acta Haematologica, 2010, 124, 103-104.	0.7	0
164	Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Acta OncolÃ³gica, 2010, 49, 506-508.	0.8	51
165	Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias. Acta OncolÃ³gica, 2010, 49, 111-112.	0.8	5
166	Efficacy and Safety of a First Line Combined Therapeutic Approach for Young CLL Patients with Advanced or Progressive Disease Stratified According to the Biologic Features: First Analysis of the GIMEMA Multicenter Study LLC0405. Blood, 2010, 116, 2471-2471.	0.6	2
167	BCR-ABLIS Expression at Diagnosis and After 3 or 6 Months of Treatment Predicts CML Response to IMATINIB Therapy.. Blood, 2010, 116, 3426-3426.	0.6	18
168	Excellent Outcomes at 3 Years with Nilotinib 800 Mg Daily In Early Chronic Phase, Ph+ Chronic Myeloid Leukemia (CML): Results of a Phase 2 GIMEMA CML WP Clinical Trial. Blood, 2010, 116, 359-359.	0.6	14
169	Abstract 1805: Improving on Imatinib for targeted therapy of chronic myeloid leukemia: First line treatment with Nilotinib 800 mg daily results in unprecedentedly high rate of rapid, â€œdeepâ€• and stable molecular responses - Results of a phase 2 trial of the GIMEMA CML working party. , 2010, , .		0
170	Retrospective Application of European LeukemiaNet Provisional Criteria for Second-Generation TKI Chronic Myeloid Leukemia. Blood, 2010, 116, 2270-2270.	0.6	0
171	First Line Treatment with Nilotinib 800 Mg Daily Results In Unprecedentedly High Rate of Rapid, â€œDeepâ€• and Stable Molecular Responses as Assessed by a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript: Results of a Phase 2 Trial of the GIMEMA CML Working Party. Blood, 2010, 116, 2720-2720.	0.6	0
172	BCR-ABL Fusion Transcript Do Not Significantly Influence the Outcome of Chronic Myeloid Leukemia Patients In Early Chronic Phase Treated with Imatinib Mesylate: a GIMEMA CML WP Analysis.. Blood, 2010, 116, 1230-1230.	0.6	2
173	Mechanisms of Heme Oxygenase 1-Induced Resistance to Imatinib In CML Cells.. Blood, 2010, 116, 3385-3385.	0.6	0
174	Effects of the Second Generation Tyrosin Kinase Inhibitors on Osteogenic Differentiation.. Blood, 2010, 116, 3386-3386.	0.6	0
175	One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (â‰¥ 65 years) Ph+ CML Patients â€“ EudraCT Number 2007â€“005102-42, ClinicalTrials.Gov NCT 00858806.. Blood, 2010, 116, 3412-3412.	0.6	0
176	Outcome of Patients with CML Treated with Dasatinib or Nilotinib after Failure of Second Prior TKIs. Blood, 2010, 116, 2294-2294.	0.6	1
177	Successful nilotinib therapy in a CML affected patient with A380T, P407S and V468A mutations, and a previous suboptimal cytogenetic response to imatinib. Clinical Management Issues, 2010, 4, 7-11.	0.3	0
178	Uncommon long-term survival in a patient with chronic myeloid leukemia. Acta OncolÃ³gica, 2009, 48, 1215-1216.	0.8	5
179	Effects of imatinib mesylate in osteoblastogenesis. Experimental Hematology, 2009, 37, 461-468.	0.2	41
180	Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase. Leukemia Research, 2009, 33, e17.	0.4	3

#	Article	IF	Citations
181	Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCRâ€“ABL kinase domain. Leukemia Research, 2009, 33, e157-e158.	0.4	5
182	The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica, 2009, 94, 205-212.	1.7	73
183	Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. Blood, 2009, 113, 3428-3434.	0.6	59
184	Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia. Blood, 2009, 114, 4933-4938.	0.6	203
185	T/NK Lymphocytosis in CML Ph+ Patients During Dasatinib Therapy.. Blood, 2009, 114, 3279-3279.	0.6	1
186	Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.. Blood, 2009, 114, 860-860.	0.6	3
187	Aberrant Phenotypic Expression of the T-Cell-Associated Antigen CD8 on B-Cell Chronic Lymphocytic Leukemia Cells. Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology, 2009, 15, 1-3.	1.2	8
188	Results of Imatinib Dose Escalation After 36 Months of Follow-up in Chronic Myeloid Leukemia Patients with Failure or Sub-Optimal Response According to 2006 EuropeanLeukemia Net (ELN) Criteria.. Blood, 2009, 114, 3302-3302.	0.6	1
189	Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis. Leukemia Research, 2008, 32, 673-674.	0.4	13
190	High and Early Rates of Cytogenetic and Molecular Response with Nilotinib 800 Mg Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Results of a Phase 2 Trial of the GIMEMA CML Working Party. Blood, 2008, 112, 181-181.	0.6	19
191	CD200 Expression May Help in Differential Diagnosis between Mantle Cell Lymphoma (MCL) and B-Cell Chronic Lymphocytic Leukemia (B-CLL).. Blood, 2007, 110, 4672-4672.	0.6	1
192	Improvement of Tolerability and Adverse Events Occurrence during Treatment with Dasatinib Used on a Compassionate Basis in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).. Blood, 2007, 110, 4564-4564.	0.6	0
193	Role of Imatinib Mesylate in Osteoblastogenesis.. Blood, 2007, 110, 1928-1928.	0.6	1
194	BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B. Blood, 2006, 107, 1591-1598.	0.6	53
195	In Vitro Cytotoxicity of Alemtuzumab on B-CLL Cells: Differential Effect on B and T Lymphocytes.. Blood, 2006, 108, 4981-4981.	0.6	0
196	Hypoxia Induces Imatinib Resistance in CML Cell Lines.. Blood, 2006, 108, 4387-4387.	0.6	0
197	Survivin expression in chronic myeloid leukemia. Cancer Letters, 2005, 225, 105-110.	3.2	31
198	T Cell Receptor Î´-Chain Gene Rearrangement in a Novel Case of Adult NK Cell Leukemia. Acta Haematologica, 2004, 111, 225-227.	0.7	1

#	Article	IF	Citations
199	Successful treatment of advanced idiopathic myelofibrosis with imatinib mesylate. European Journal of Haematology, 2004, 73, 147-148.	1.1	4
200	Flow cytometric detection of aneuploid CD38++ plasmacells and CD19+ B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients. Leukemia Research, 2004, 28, 469-477.	0.4	57
201	VLA-2 and VLA-5 Cell Adhesion Molecules Expression in CD34+ Cells from Umbilical Cord Blood and from Bone Marrow. Blood Purification, 2002, 20, 174-176.	0.9	1
202	Multidrug resistance mechanisms in chronic lymphocytic leukaemia. British Journal of Haematology, 2002, 116, 774-780.	1.2	35
203	Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis. Leukemia, 2001, 15, 976-980.	3.3	80
204	Successful Treatment of Granulocytic Sarcoma with Î±-Interferon and Disodium Pamidronate at Presentation of Chronic Myeloid Leukemia. Acta Haematologica, 2001, 105, 116-117.	0.7	1
205	In vitro Apoptotic Response of Freshly Isolated Chronic Myeloid Leukemia Cells to all-trans Retinoic Acid and Cytosine Arabinoside. Acta Haematologica, 2000, 104, 57-64.	0.7	3
206	All-Trans-Retinoic-Acid- and Growth-Factor- Mediated Induction of Alkaline Phosphatase Activity in Freshly Isolated Chronic Myeloid Leukemia Cells. Acta Haematologica, 1999, 102, 61-65.	0.7	5
207	Role of interferon regulatory factor 1 in monocyte/macrophage differentiation. European Journal of Immunology, 1999, 29, 3009-3016.	1.6	17
208	Successful Healing of Hydroxyurea-Related Leg Ulcers With Topical Granulocyte-Macrophage Colony-Stimulating Factor. Blood, 1999, 94, 1479-1480.	0.6	2
209	Evaluation of taxol cytotoxicity on B-CLL cells in vitro. Leukemia and Lymphoma, 1997, 26, 115-119.	0.6	9
210	Indagine Sui Vegetali Causa di Degrado dei Monumenti Della Citta' di Noto (Sicilia Orientale). Giornale Botanico Italiano (Florence, Italy: 1962), 1996, 130, 457-457.	0.0	2
211	CD34 Expression in Adult Acute Lymphoblastic Leukemia. Leukemia and Lymphoma, 1995, 18, 31-36.	0.6	9
212	Hypereosinophilia and subcutaneous heparin. Lancet, The, 1993, 342, 1371.	6.3	9